ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2025

Correction to 'Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study'.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.